Immatics US, Inc.
This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the recommended phase 2 dose versus investigator's choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma or mucosal melanoma (MM). For patients interested in additional information on how to participate, please follow this link: https://mytomorrows.com/trials/suprame/en-us/
SCREENING: Patient eligibility will be determined by protocol inclusion/exclusion criteria including HLA (human leukocyte antigen) screening. Leukapheresis for potential manufacturing of the IMA203 cellular product may be performed, if patients are positive HLA-A\*02:01 or one of its P-group alleles and meet the eligibility criteria for leukapheresis. MANUFACTURING: IMA203 products will be made from the patients' white blood cells. TREATMENT- Experimental arm: Lymphodepletion with cyclophosphamide and fludarabine will occur in the days before the IMA203 product infusion to improve the durati…
Inclusion Criteria: * Pathologically confirmed and documented cutaneous melanoma or mucosal melanoma. CM patients (including acral melanoma and melanoma of unknown primary) and mucosal melanoma patients with unresectable or metastatic disease * Positive for HLA-A\*02:01 or one of its P-group alleles * Adequate selected organ function per protocol * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Disease progression (resistance, toxicity) on or after at least one PD-1 inhibitor, applied either as monotherapy or in combination with other therapies as treatment for unresectabl…
one-time administration of IMA203, and adjunctive therapy with low dose interleukin (IL)-2 for up to 10 days, starting approximately 24 h after IMA203 infusion, optional bridging therapy
in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)